Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
26 hedge funds and large institutions have $6M invested in Soleno Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
18% more funds holding
Funds holding: 22 → 26 (+4)
15% more capital invested
Capital invested by funds: $5.23M → $6M (+$777K)
1.49% less ownership
Funds ownership: 38.64% → 37.15% (-1.5%)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$83.9K |
| 2 |
Millennium Management
New York
|
+$57.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$24.8K |
| 4 |
E
Ergoteles
New York
|
+$15.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$295K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$88.5K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$15.6K |
| 4 |
CP
Clayton Partners
Berkeley,
California
|
-$8.99K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.99K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| – | -$5 | -4 | -40% |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$4 | -3 | -33% |
|
SLNO Hedge Fund Activity: Q4 2022 in Review
26 of the 6,225 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2022, worth a combined $6M — up 15% from $5.23M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SLNO positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was J. Goldman & Co, adding an estimated $83.9K. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $295K sold.
- 26 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2022, up from 22 in Q3 2022.
- Funds reported $6M of Soleno Therapeutics stock for Q4 2022, up 15% quarter-over-quarter.
- 6 funds opened new Soleno Therapeutics positions in Q4 2022 and 2 closed out, a net change of +4 holders.
- The largest Soleno Therapeutics buyer in Q4 2022 was J. Goldman & Co, an estimated $83.9K added.
- The largest Soleno Therapeutics seller in Q4 2022 was Granite Point Capital Management, an estimated $295K sold.
Based on aggregated 13F filings for Q4 2022.